EMBC UPCOMING DEADLINE: SueWallSt Alerts Embecta Corp. Stockholders of Securities Class Action - Contact the Firm

SueWallSt alerts investors in Embecta Corp. (NASDAQ: EMBC) of a pending securities class action. Class Period: November 25, 2025 through May 4, 2026.

Embecta shares lost $5.35 per share on May 5, 2026, falling from $9.25 to $3.90, a single-day decline of 57.8%. The Court has set August 17, 2026 as the deadline to apply for lead plaintiff appointment.

The lawsuit asserts that throughout the Class Period, management painted an optimistic picture of Embecta's pen needle segment while concealing that the Company was experiencing significant share loss concentrated at a single major customer. As alleged, this customer concentration risk was material because patients switching to competitors at that account were disproportionately those not on payer plans where Embecta held preferred access, meaning revenue impact per lost unit was far greater than average pricing would suggest.

The action claims management described pen needles as "incredibly resolute" at an industry conference in January 2026 and reaffirmed full-year guidance in February 2026, even as these competitive dynamics were allegedly already eroding the Company's U.S. market position.

Beyond single-customer share loss, the lawsuit contends that Embecta faced a second concealed headwind: overall market volume softness for insulin pens and pen needles in the retail channel. As alleged, more patients were choosing to acquire pen needles from channels where Embecta does not participate or where products carry lower prices, creating additional pressure on retail volumes that management failed to disclose.

This channel migration allegedly compounded the competitive share loss, producing a combined revenue miss that dwarfed what investors had been led to expect:

Pen needle revenue alone was reduced by approximately $53 million, accounting for 70% of the total $75 million guidance cut

Competitive share loss at the single customer drove an estimated $25 million of that pen needle reduction

Overall market volume softness accounted for an additional estimated $20 million

Inventory reductions and net pricing pressure at certain accounts contributed approximately $8 million more

Syringe revenue declined by approximately $13 million, partly from lower use associated with compounded drugs

Patients migrating to lower-cost purchasing channels created pressure that management had not previously disclosed

"Investors deserve transparency about material risks that could affect their investments. The complaint raises important questions about whether known competitive and channel dynamics were adequately communicated to shareholders who were purchasing stock at prices reflecting reaffirmed guidance." -- Joseph E. Levi, Esq.